Navigating the Clinical Trial Process for Hepatocellular Carcinoma
- Conditions
- Hepatocellular Carcinoma
- Registration Number
- NCT05859945
- Lead Sponsor
- Power Life Sciences Inc.
- Brief Summary
Clinical trials can sometimes favor certain demographic groups. Additionally, there is limited research that delves into the factors that influence participation in clinical study, both positive and negative.
The goal is to identify the obstacles and challenges that prevent participation in hepatocellular carcinoma clinical research, as well as the reasons for withdrawal or discontinuation.
Insights gained from this study will ultimately benefit those with hepatocellular carcinoma who may be invited to participate in clinical research in the years to come.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 500
- Diagnosed with hepatocellular carcinoma
- Willing to comply with all study related procedures and assessments
- Capable of giving signed informed consent, which includes compliance with requirements and restrictions listed in the informed consent form (ICF) and in the protocol
- No documented diagnosis of hepatocellular carcinoma
- Any serious and/or unstable pre-existing medical disorders
- Pregnant or lactating woman
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Number of hepatocellular carcinoma study participants who remain in clinical trial until completion. 12 months Rate of patients who decide to enroll in a hepatocellular carcinoma clinical study. 3 months
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.